Rigel Pharmaceuticals, Inc. (RIGL)
Valuation Overview•Is Rigel Pharmaceuticals, Inc. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
High-quality fundamentals with a strong composite quality score of 88/100, backed by robust profitability and solvency.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Verdict: Elite compounder with fortress-level fundamentals across every core pillar.
Wall Street is cautious, forecasting potential downside. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
RIGL exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins (highlighted by a massive 45.8% ROIC). This is paired with a moderately leveraged but stable balance sheet.
The company is driving exceptional top-line expansion (34.8% 3Y CAGR) paired with stable bottom-line earnings. This growth is supported by elite operational efficiency, sustaining an impressive 41.6% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $58.8M | +64.1% | +34.8% | +22.1% | +26.1% | |
| EBITDA | $11.9M | — | — | — | — | |
| Net Income | $8.7M | +1999.1% | — | — | — | |
| EPS (Diluted) | $0.44 | +1867.7% | — | — | — | |
| Free Cash Flow | $2.7M | +143.5% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 93.4% | 92.3% | 94.9% | -37.1% |
| Operating Margin | 41.6% | 12.9% | -3.2% | -244.0% |
| Net Margin | 121.5% | 37.7% | 10.5% | -232.5% |
| FCF Margin | 26.4% | 8.4% | -6.6% | -239.9% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.74 | $0.44 | -40.5% | ||
| Q1'26 | $1.33 | $1.14 | -14.3% | ||
| Q4'25 | $0.93 | $1.46 | +57.0% | ||
| Q3'25 | $1.97 | $3.28 | +66.5% | ||
| Q2'25 | $0.14 | $0.63 | +350.0% | ||
| Q1'25 | $0.30 | $0.80 | +166.7% | ||
| Q4'24 | $0.06 | $0.70 | +1066.7% | ||
| Q3'24 | $-0.37 | $-0.06 | +83.8% |
Total return is +70.0% (1Y), outperforming the benchmark by +45.0%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -21.3% | -30.6% | — |
| 1Y | +70.0% | +45.0% | — |
| 3YCAGR | +28.3% | +9.3% | — |
| 5YCAGR | -4.9% | -17.0% | — |
| 10YCAGR | +3.0% | -10.3% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Rigel Pharmaceuticals, Inc. (RIGL) valuation, health, and returns.
Based on peer relative multiples, Rigel Pharmaceuticals, Inc. appears Cheap versus peers compared to industry peers.
Rigel Pharmaceuticals, Inc. has multiple valuation anchors: Peer Relative Fair Value: $168.03 | Wall Street Analyst Target: $27.33 (implying -17.0% upside). A convergence of these signals offers higher conviction.
Rigel Pharmaceuticals, Inc. displays excellent financial health with a composite quality score of 88/100, supported by a Altman Z-Score of 1.9 (grey zone), Piotroski F-Score of 6/9, Return on Invested Capital (ROIC) of 45.8%.
Rigel Pharmaceuticals, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Rigel Pharmaceuticals, Inc.'s current growth trajectory is Accelerating. The company achieved +64.1% 1Y revenue growth and +1867.7% 1Y EPS growth, compared to its 3Y revenue CAGR of +34.8%.
Wall Street consensus is Buy based on 15 analysts, beating EPS expectations in 75% of recent quarters with a -2-quarter streak. The consensus price target represents a -17.0% change from current levels.
Investment risks for Rigel Pharmaceuticals, Inc. include: -50.1% 1-year max drawdown. Volatility risk is characterized by a beta of 0.94x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.